At today's poster session, Andrea Ziblat, PhD will be presenting exciting work on how FGFR3 is shaping the immune landscape affecting PD-1/PD-L1 treatment efficacy. Stop by her poster and learn more about immunotherapy resistance in bladder cancer.
@UChicagoHemOnc

#AACR26